Literature DB >> 332193

[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].

P A Fischer, P Jacobi, E Schneider, B Schönberger.   

Abstract

After a preliminary study in 6 parkinsonian patients concerning the effectiveness and tolerance of 1,3-dimethyl-5-aminoadamantane hydrochloride (memantine) an investigation to assess its short-term effects was performed. In an unselected group of 12 parkinsonian patients 40 mg of memantine diluted in 500 ml of laevulose were applied i.v. within 2 h. The patients were examined under standardized conditions before, immediately after and 2, 4 and 24 h, respectively, using a program of physchological tests. The results give evidence for a favourable influence on rigor and tremor in Parkinson's syndrome as well as on motor drive. In comparative studies memantine showed a better tolerance than adamantylaminosulfate. The short-time effects of the drug could be differentiated from placebo and learning effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 332193

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ9 -tetrahydrocannabinol.

Authors:  Ilya D Ionov; Irina I Pushinskaya; David D Frenkel; Niсholas P Gorev; Larissa A Shpilevaya
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

Review 2.  Memantine.

Authors:  Blair Jarvis; David P Figgitt
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

Review 4.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  [The role of cochlear neurotransmitters in tinnitus].

Authors:  B Mazurek; T Stöver; H Haupt; J Gross; A Szczepek
Journal:  HNO       Date:  2007-12       Impact factor: 1.284

6.  Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio.

Authors:  B S Meldrum; L Turski; M Schwarz; S J Czuczwar; K H Sontag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

7.  Behavioral disturbances in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

Review 8.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Authors:  Stuart J Thomas; George T Grossberg
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

Review 9.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.

Authors:  Caroline Moreau; Arnaud Delval; Vincent Tiffreau; Luc Defebvre; Kathy Dujardin; Alain Duhamel; Gregory Petyt; Claude Hossein-Foucher; David Blum; Bernard Sablonnière; Susanna Schraen; Delphine Allorge; Alain Destée; Régis Bordet; David Devos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-16       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.